Cell Genesys Halts VITAL-2 GVAX Trial In Advanced Prostate Cancer

�Cell Genesys, Inc. (Nasdaq:CEGE) announced that it has terminated VITAL-2, the sec of deuce Phase 3 clinical trials of GVAX immunotherapy for prostate genus Cancer, which compares GVAX immunotherapy in combination with Taxotere� (docetaxel) to Taxotere summation prednisone in patients with advanced-stage prostate gland cancer. The Company concluded the trial as recommended by its Independent Data Monitoring Committee (IDMC) which, in a routine safety device review meeting held this week, observed an